Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Emmessar Biotech & Nutrition has sent a cover letter to BSE (Scrip Code: 530825) attaching copies of its Q2 FY26 financial results (quarter ended September 30, 2025) published in Free Press Journal and Nav Shakti newspapers on November 13, 2025. The company operates two segments — Healthcare and Rent on leasehold land. Total Revenue from Operations for Q2 FY26 stood at around ₹18,502.72 lakhs, with Profit Before Tax of ₹6,382.47 lakhs and Net Profit After Tax of ₹4,580.15 lakhs. The Board approved the results on November 12, 2025, statutory auditors gave an unqualified limited review opinion, and no investor complaints were received for the quarter.
This is a routine regulatory compliance filing — a paper publication of already-filed results, not new information. No direct impact on shareholders or stock price; the underlying Q2 numbers (revenue around ₹18,500 lakhs, healthy PAT margin) suggest stable operations, but detailed performance review would need the full results PDF on BSE.